John Poyhonen compensation by year
Heron Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Salary | $216,731 | $513,935 | $509,748 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $314,400 | $583,626 |
| Option awards | $4,211,063 | $1,635,349 | $535,147 |
| Non-equity incentive | $90,751 | $197,960 | $203,899 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $6,219 | $8,550 | $8,700 |
| Total | $4,524,764 | $2,670,194 | $1,841,120 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Heron Therapeutics, Inc. DEF 14A filed April 25, 2022, accession 0001564590-22-015345, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Heron Therapeutics, Inc. filed document, accession 0001564590-22-015345. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 87,129 | — | $10.55 |
| Option | 118,750 | — | $18.29 |
| Option | 27,781 | — | $25.02 |
| Option | 120,417 | — | $15.72 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Heron Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2021 proxy (filed April 25, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2023-04-13 | Exercise or conversion | — | 1,250 | — | 44,096 |
| 2023-04-13 | Exercise or conversion | — | 4,564 | — | 48,660 |
| 2023-04-13 | Tax withholding | — | 2,012 | $2.88 | 46,648 |
| 2023-04-13 | Exercise or conversion derivative | — | 1,250 | $0.00 | 7,500 |
| 2023-04-13 | Exercise or conversion derivative | — | 4,564 | $0.00 | 27,936 |
| 2023-01-18 | Grant or award derivative | — | 66,385 | $0.00 | 66,385 |
| 2023-01-13 | Exercise or conversion | — | 4,564 | — | 44,858 |
| 2023-01-13 | Tax withholding | — | 2,012 | $3.17 | 42,846 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Heron Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Barry Quart | Former Chief Executive Officer | $5,430,828 |
| Kimberly Manhard | Executive Vice President, Drug Development | $1,858,578 |
| John Poyhonen · this page | President and Chief Commercial Officer | $1,841,120 |
| David Szekeres | Executive Vice President, Chief Operating Officer | $1,829,431 |
| Lisa Peraza | Vice President, Chief Accounting Officer | $796,755 |
The full Heron Therapeutics compensation record
free company briefThis page is one person within Heron Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Heron Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Heron Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.